About CytoSolv
CytoSolv is a Healthcare company based in Newport (United States) founded in 2009, and was acquired by Semma Therapeutics in November 2015. Biotech company developing encapsulating cell technology for indications in cell therapy; acquired by Semma Therapeutics in 2015. CytoSolv has raised $500 thousand across 5 funding rounds from investors including Semma Therapeutics, National Science Foundation and Slater Technology Fund. The company was acqui-hired. Its focus areas include Life Sciences, Cell Therapy, Stem Cells and Progenitor Cells. Its competitors include Sana Biotechnology, Semma Therapeutics and Rezolute; 2 of its 3 listed competitors have raised funding.
Company details
CytoSolv was founded in 2009 in Newport, United States, as a biotech firm focused on encapsulating cell technology within the cell therapy sector. Initial efforts targeted therapies for diabetic foot ulcer wound healing, with operations later shifted toward broader encapsulating applications. The company was acquired by Semma Therapeutics on November 16, 2015, concluding its independent development activities.
- Headquarters Newport, United States
- Stage Acquired
- SectorsHealthcare
- Website cytosolv.com
- Social LinkedIn
- Acquired by Semma Therapeutics (Nov 2015)
- Total Equity Funding$500K (USD)
in 5 rounds
- Latest Funding Round$150K (USD), Grant
Jan 2013
- InvestorsSemma Therapeutics
& 3 more
- Acquired bySemma Therapeutics
(Nov 2015)
Funding Insights of CytoSolv
CytoSolv has successfully raised a total of $500K across 5 strategic funding rounds. The most recent funding activity was a Grant round of $150 thousand completed in January 2013. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $500,000
- Total Rounds 5
- Last Round Grant — $150,000
- First Round $500,000
(Feb 2010)
- Investors Count 3
All 5 funding rounds of CytoSolv with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2013 | $150,000 | Grant | – | – | |
| Sep 2011 | $225,683 | Grant | – | – | |
| Jan 2011 | $150,000 | Grant | – | – | |
| Nov 2010 | $179,999 | Grant | – | – | |
| Feb 2010 | $500,000 | Seed | – | – |
4 investors in total: 4 institutional.
Investors in CytoSolv
CytoSolv has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include Semma Therapeutics, National Science Foundation and Slater Technology Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
VC investments are directed toward US and UK companies. | slaterfund.com | Providence, United States | ||
A government-backed foundation providing seed-stage investments to support small businesses. | 1950 | nsf.gov | Arlington, United States | |
Develops cell therapy treatments for neurodegenerative diseases. | 1999 | lctglobal.com | Auckland, New Zealand | |
Provider of bio-artificial pancreas for Type 1 Diabetes treatment | 2015 | semma-tx.com | Cambridge, United States |
Investor details for CytoSolv
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of CytoSolv
4 dated milestones of CytoSolv across 6 years, from founding to its latest funding, stage changes and deals.
- Founded CytoSolv is founded.
- Funding First funding round of $500K.
- Funding Latest funding round, Grant, of $150K.
- Exit Acquired by Semma Therapeutics.
Competitors of CytoSolv
CytoSolv has 3 listed competitors in our database, 2 of them funded. They include Sana Biotechnology, Semma Therapeutics and Rezolute.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| sana.com | 2018 | Seattle, United States | $821M | 328 | Genetically engineered cell therapies are developed for multiple disorders. | |
| semma-tx.com | 2015 | Cambridge, United States | $158M | 58 | Provider of bio-artificial pancreas for Type 1 Diabetes treatment | |
| rezolutebio.com | 2012 | Denver, United States | 51 | Therapies for metabolic and orphan diseases are developed by Rezolute. |
Detailed competitors of CytoSolv
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Cell Therapy
3 companies that operate in the same segment as CytoSolv (Cell Therapy) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | 520 | ||
CAR-T and TIL immunotherapies for solid tumors are developed. | 2018 | San Francisco, California, United States | USD 493 M | USD 36 K | 233 | |
Smart surgical devices for spinal surgery are developed. | 1997 | San Diego, California, United States | USD 54.1 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about CytoSolv
CytoSolv was founded in 2009 and raised its 1st funding round 1 year after it was founded.
CytoSolv is headquartered in Newport, United States. It is registered at Newport, Rhode Island, United States.
CytoSolv is a funded company, having raised a total of $500K across 5 funding rounds to date. The company's 1st funding round was a Seed of $500K, raised on Feb 2010.
CytoSolv was founded in 2009 in Newport, United States, as a biotech firm focused on encapsulating cell technology within the cell therapy sector. Initial efforts targeted therapies for diabetic foot ulcer wound healing, with operations later shifted toward broader encapsulating applications. The company was acquired by Semma Therapeutics on November 16, 2015, concluding its independent development activities.
CytoSolv's top competitors include Sana Biotechnology, Semma Therapeutics and Rezolute.
CytoSolv has 4 investors. Key investors include Semma Therapeutics, National Science Foundation, Slater Technology Fund, and Living Cell Technologies.
Yes. CytoSolv was acquired by Semma Therapeutics in November 2015.